RecruitingPhase 2NCT02939573

A Randomized Multicenter Study for Isolated Skin Vasculitis

Sponsor

University of Pennsylvania

Enrollment

90 participants

Start Date

Jan 1, 2017

Study Type

INTERVENTIONAL

Conditions

IgA Vasculitis Henoch-Schönlein Purpura Primary Cutaneous Vasculitis Cutaneous Polyarteritis Nodosa

Summary

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Azathioprine, a drug called Colchicine, and others for people with cutaneous polyarteritis nodosa, henoch-schönlein purpura, and other related conditions. The study is currently recruiting participants at 16 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGColchicine

Randomized to colchicine 0.6 mg x 2/day

DRUGDapsone

Randomized to dapsone 150 mg/day

DRUGAzathioprine

Randomized to azathioprine 2 mg/kg/day

Locations(16)

University of Kansas Medical Center

Kansas City, Kansas, United States

Boston University School of Medicine

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Northwell Health

Lake Success, New York, United States

Hospital for Special Surgery

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

Penn State Hershey Medical Center

Hershey, Pennsylvania, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Vanderbilt University

Nashville, Tennessee, United States

UT Southwestern Medical Center

Dallas, Texas, United States

University of Utah

Salt Lake City, Utah, United States

University of Virginia

Charlottesville, Virginia, United States

St. Joseph's Healthcare

Hamilton, Ontario, Canada

University of Toronto Mount Sinai Hospital

Toronto, Ontario, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Tohoku Medical and Pharmaceutical University Hospital

Kyoto, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02939573

Related Trials

I-FABP as a Predictor of Gastrointestinal Involvement in Pediatric IgA Vasculitis

NCT076642281 location

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT0500398647 locations